Hims & Hers opens $149 waitlist for branded Wegovy and Ozempic

Hims & Hers has opened a waitlist for branded Wegovy and Ozempic at $149 a month through its partnership with Novo Nordisk, the lowest self-pay price the platform has offered for branded semaglutide ^[1]. A Hims & Hers news timeline lists a waitlist launch for the same $149 offer under a March 19, 2026 date ^[1].

Wegovy and Ozempic are Novo Nordisk's brand-name versions of semaglutide. The two companies announced a joint obesity-drug partnership on March 7, 2026, after resolving a legal dispute, and Hims & Hers said on March 27, 2026 that it was expanding its weight-loss portfolio with Novo Nordisk GLP-1 products ^[1].

The $149 price is tied to a wider change in the company's business. Hims & Hers shifted from compounded semaglutide to branded medication, a move it has said compressed gross margin by roughly 12 points to 64 percent while expanding its addressable market ^[1]. After the FDA took semaglutide off the drug-shortage list, effectively ending the compounding channel, the company moved US patients onto branded GLP-1 drugs such as Wegovy ^[2].

The financial cost shows in the second quarter of 2026. Revenue rose 38 percent to $753.2 million, beating the roughly $699 million analysts expected, but the adjusted loss was $0.10 a share against an expected $0.07 ^[2]. Gross margin fell from 76 percent a year earlier to 64 percent, and adjusted EBITDA margin dropped from 15 percent to 8 percent ^[2]. The quarter produced an $86.3 million GAAP net loss and $68.2 million of negative free cash flow, while the company added 300,000 net subscribers ^[2]. Hims & Hers has reported filling more than 125,000 Wegovy shipments within six weeks of the branded launch ^[1].

Guidance has moved in two directions. The full-year 2026 revenue midpoint went from $2.8 billion in February to $2.9 billion in May to $3.2 billion in August, while the adjusted EBITDA range was cut from $300–375 million to $275–325 million ^[2].

Why it matters for patients

For people who pay cash for semaglutide because their insurance does not cover it, or because they have no coverage, $149 a month is the lowest price Hims & Hers has advertised for the branded versions of the drug ^[1]. That price is for the medication through the platform; the sources do not say whether clinical visits, lab work, shipping or other fees are included, whether the price changes by dose, who is eligible, or which states the offer will cover.

The offer is a waitlist, not an immediate purchase, so joining does not guarantee access on any given date ^[1]. Hims & Hers has not disclosed how long the waitlist is, when it will open, or how many patients it expects to serve.

The shift also removes an option some patients were already using. With the FDA action ending the compounding channel, cheaper compounded semaglutide is no longer the large-scale alternative it was ^[2]. Patients who had been filling compounded prescriptions through such platforms may need to move to a branded product or another source, and the sources do not describe how, or whether, those patients are being transitioned.

The $149 price is a business decision made while the company's margins are compressed ^[1][2]. Whether the price holds, and on what terms, has not been reported.

What happens next

Hims & Hers has committed to returning to net profitability in 2027 ^[2]. According to a September analysis of the company's results, the transition would look complete if gross margin holds near 64 percent rather than sliding toward 60 percent through the second half of 2026, and if full-year adjusted EBITDA lands near the middle of the $275–325 million range rather than at the bottom ^[2]. The same analysis notes that the business still loses money on a GAAP basis on a trailing-year basis ^[2].

A date for when the $149 waitlist converts to active orders has not been disclosed ^[1].